Breaking Finance News

Acceleron Pharma Inc (NASDAQ:XLRN) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded Acceleron Pharma Inc (NASDAQ:XLRN) to Hold in a statement released on 10/12/2016.

Boasting a price of $33.76, Acceleron Pharma Inc (NASDAQ:XLRN) traded -7.95% lower on the day. The last stock close price is up -5.06% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. Acceleron Pharma Inc has recorded a 50-day average of $34.13 and a two hundred day average of $32.70. Volume of trade was down over the average, with 133,396 shares of XLRN changing hands under the typical 258,986

Performance Chart

Acceleron Pharma Inc (NASDAQ:XLRN)

With a total market value of $0, Acceleron Pharma Inc has with a one year low of $21.93 and a one year high of $50.86 .

A total of 9 analysts have released a research note on XLRN. Four analysts rating the company a strong buy, four analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $47.33.

More About Acceleron Pharma Inc (NASDAQ:XLRN)

Acceleron Pharma Inc. is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia. Its Sotatercept is an investigational protein therapeutic that manages red blood cell levels by targeting molecules in the transforming growth factor beta (TGF-β) superfamily, which is being evaluated in Phase IIa studies. Its Dalantercept is an investigational protein therapeutic that inhibits angiogenesis by preventing bone morphogenetic proteins 9 (BMP) and BMP10, proteins in the TGF-β superfamily, which is being evaluated in Phase II studies. Its ACE-083 is an investigational protein therapeutic that helps to manage muscle mass and strength in specific muscles and muscle groups, which is being evaluated in Phase I studies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *